The COVID-19 patients showed hyperinflammatory response depending on the severity of the disease but little have been reported about this response in oncologic patients that also were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sixty-five circulating cytokines/chemokines were quantified in 15 oncologic patients, just after SARS-CoV-2 infection and fourteen days later, and their levels were compared in patients who required hospitalisation by COVID-19 versus non-hospitalised patients. A higher median age of 72 years (range 61–83) in oncologic patients after SARS-CoV-2 infection was associated with hospitalisation requirement by COVID-19 versus a median age of 49 years (20–75) observed in the non-hospitalised oncologic patients (p = 0.008). Moreover, oncologic patients at metastatic stage or with lung cancer were significantly associated with hospitalisation by COVID-19 (p = 0.044). None of these hospitalised patients required ICU treatment. Higher basal levels of tumour necrosis factor receptor II (TNF-RII), interferon-γ (IFNγ)-induced protein 10 (IP-10) and hepatocyte growth factor (HGF) in plasma were significantly observed in oncologic patients who required hospitalisation by COVID-19. Higher TNF-RII, IP-10 and HGF levels after the SARS-CoV-2 infection in oncologic patients could be used as biomarkers of COVID-19 severity associated with hospitalisation requirements.

中文翻译：

---

循环中的 TNF-RII、IP-10 和 HGF 与肿瘤患者中 COVID-19 的严重程度相关

COVID-19 患者根据疾病的严重程度表现出高炎症反应，但关于同时感染严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的肿瘤患者的这种反应的报道很少。在 SARS-CoV-2 感染后和 14 天后，对 15 名肿瘤患者的 65 种循环细胞因子/趋化因子进行了定量，并将因 COVID-19 住院的患者与非住院患者的水平进行了比较。SARS-CoV-2 感染后肿瘤患者的中位年龄较高，为 72 岁（范围 61-83），与 COVID-19 的住院要求相关，而非住院患者的中位年龄为 49 岁（20-75 岁）。肿瘤患者（p = 0.008）。此外，处于转移期或肺癌的肿瘤患者与因 COVID-19 住院显着相关（p = 0.044）。这些住院患者均不需要 ICU 治疗。在因新冠肺炎而需要住院的肿瘤患者中，血浆中肿瘤坏死因子受体 II (TNF-RII)、干扰素-γ (IFNγ) 诱导蛋白 10 (IP-10) 和肝细胞生长因子 (HGF) 的基础水平显着升高-19。肿瘤患者感染 SARS-CoV-2 后较高的 TNF-RII、IP-10 和 HGF 水平可用作与住院要求相关的 COVID-19 严重程度的生物标志物。